Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment.

Araujo, AM; Abaurrea, A; Azcoaga, P; López-Velazco, JI; Manzano, S; Rodriguez, J; Rezola, R; Egia-Mendikute, L; Valdés-Mora, F; Flores, JM; Jenkins, L; Pulido, L; Osorio-Querejeta, I; Fernández-Nogueira, P; Ferrari, N; Viera, C; Martín-Martín, N; Tzankov, A; Eppenberger-Castori, S; Alvarez-Lopez, I; Urruticoechea, A; Bragado, P; Coleman, N; Palazón, A; Carracedo, A; Gallego-Ortega, D; Calvo, F; Isacke, CM; Caffarel, MM; Lawrie, CH

Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment.

Araujo, AM Abaurrea, A Azcoaga, P López-Velazco, JI Manzano, S Rodriguez, J Rezola, R Egia-Mendikute, L Valdés-Mora, F Flores, JM Jenkins, L Pulido, L Osorio-Querejeta, I Fernández-Nogueira, P Ferrari, N Viera, C Martín-Martín, N Tzankov, A Eppenberger-Castori, S Alvarez-Lopez, I Urruticoechea, A Bragado, P Coleman, N Palazón, A Carracedo, A Gallego-Ortega, D Calvo, F Isacke, CM Caffarel, MM Lawrie, CH

Permalink

Publisher:: AMER SOC CLINICAL INVESTIGATION INC
Publication Type:: Journal Article
Citation:: J Clin Invest, 2022, 132, (19), pp. e165107
Issue Date:: 2022-10-03

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Download Published versionAdobe PDF (179.39 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Araujo, AM
dc.contributor.author	Abaurrea, A
dc.contributor.author	Azcoaga, P
dc.contributor.author	López-Velazco, JI
dc.contributor.author	Manzano, S
dc.contributor.author	Rodriguez, J
dc.contributor.author	Rezola, R
dc.contributor.author	Egia-Mendikute, L
dc.contributor.author	Valdés-Mora, F
dc.contributor.author	Flores, JM
dc.contributor.author	Jenkins, L
dc.contributor.author	Pulido, L
dc.contributor.author	Osorio-Querejeta, I
dc.contributor.author	Fernández-Nogueira, P
dc.contributor.author	Ferrari, N
dc.contributor.author	Viera, C
dc.contributor.author	Martín-Martín, N
dc.contributor.author	Tzankov, A
dc.contributor.author	Eppenberger-Castori, S
dc.contributor.author	Alvarez-Lopez, I
dc.contributor.author	Urruticoechea, A
dc.contributor.author	Bragado, P
dc.contributor.author	Coleman, N
dc.contributor.author	Palazón, A
dc.contributor.author	Carracedo, A
dc.contributor.author	Gallego-Ortega, D
dc.contributor.author	Calvo, F
dc.contributor.author	Isacke, CM
dc.contributor.author	Caffarel, MM
dc.contributor.author	Lawrie, CH
dc.date.accessioned	2023-02-27T19:10:06Z
dc.date.available	2023-02-27T19:10:06Z
dc.date.issued	2022-10-03
dc.identifier.citation	J Clin Invest, 2022, 132, (19), pp. e165107
dc.identifier.issn	0021-9738
dc.identifier.issn	1558-8238
dc.identifier.uri	http://hdl.handle.net/10453/166463
dc.description.abstract	The authors recently became aware that, following the recent update of Cancertool (http://genomics.cicbiogune.es/CANCERTOOL/index.html), the two panels included in Supplemental Figure 3B needed to be modified. These panels included data downloaded from Cancertool reporting the prognostic potential of OSM in two independent breast cancer patient datasets, namely METABRIC (PMID 22522925) and Wang et al. (PMID 15721472). Based on the results from the updated Cancertool data, we cannot conclude that OSM is shown to exhibit prognostic potential in the Wang dataset. In addition, the analysis of the METABRIC dataset presented in Supplemental Figure 3B pertains to overall survival, but data were inadvertently reported as showing disease-free survival. The corrected panels are shown below. Corrected sentences referring to Supplemental Figure 3B data in Results and Methods are also shown below. The online supplemental file has been updated. Results We also observed that increased OSM mRNA levels associated with decreased overall survival in the METABRIC (19) breast cancer dataset (Supplemental Figure 3B). Of note, the prognostic analysis of OSM in the Wang (20) dataset did not reveal a significant association with disease-free survival (Supplemental Figure 3B). Methods Gene expression analyses of clinical datasets and bioinformatics analyses. Overall survival (OS) and disease-free survival (DFS) data for breast cancer patients based on OSM mRNA expression in the METABRIC (19) and Wang (20) datasets were analyzed and represented using the CANCERTOOL interface (59) in combination with cBioPortal (www.cbioportal.org).
dc.format	Electronic
dc.language	eng
dc.publisher	AMER SOC CLINICAL INVESTIGATION INC
dc.relation.ispartof	J Clin Invest
dc.relation.isbasedon	10.1172/JCI165107
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	11 Medical and Health Sciences
dc.subject.classification	Immunology
dc.subject.mesh	Breast Neoplasms
dc.subject.mesh	Cell Line, Tumor
dc.subject.mesh	Female
dc.subject.mesh	Humans
dc.subject.mesh	Oncostatin M
dc.subject.mesh	Stromal Cells
dc.subject.mesh	Tumor Microenvironment
dc.subject.mesh	Cell Line, Tumor
dc.subject.mesh	Stromal Cells
dc.subject.mesh	Humans
dc.subject.mesh	Breast Neoplasms
dc.subject.mesh	Female
dc.subject.mesh	Oncostatin M
dc.subject.mesh	Tumor Microenvironment
dc.subject.mesh	Breast Neoplasms
dc.subject.mesh	Cell Line, Tumor
dc.subject.mesh	Female
dc.subject.mesh	Humans
dc.subject.mesh	Oncostatin M
dc.subject.mesh	Stromal Cells
dc.subject.mesh	Tumor Microenvironment
dc.title	Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment.
dc.type	Journal Article
utslib.citation.volume	132
utslib.location.activity	United States
utslib.for	11 Medical and Health Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
pubs.organisational-group	/University of Technology Sydney/Centre for Health Technologies (CHT)
utslib.copyright.status	open_access	*
dc.date.updated	2023-02-27T19:10:05Z
pubs.issue	19
pubs.publication-status	Published online
pubs.volume	132
utslib.citation.issue	19

Abstract:

The authors recently became aware that, following the recent update of Cancertool (http://genomics.cicbiogune.es/CANCERTOOL/index.html), the two panels included in Supplemental Figure 3B needed to be modified. These panels included data downloaded from Cancertool reporting the prognostic potential of OSM in two independent breast cancer patient datasets, namely METABRIC (PMID 22522925) and Wang et al. (PMID 15721472). Based on the results from the updated Cancertool data, we cannot conclude that OSM is shown to exhibit prognostic potential in the Wang dataset. In addition, the analysis of the METABRIC dataset presented in Supplemental Figure 3B pertains to overall survival, but data were inadvertently reported as showing disease-free survival. The corrected panels are shown below. Corrected sentences referring to Supplemental Figure 3B data in Results and Methods are also shown below. The online supplemental file has been updated. Results We also observed that increased OSM mRNA levels associated with decreased overall survival in the METABRIC (19) breast cancer dataset (Supplemental Figure 3B). Of note, the prognostic analysis of OSM in the Wang (20) dataset did not reveal a significant association with disease-free survival (Supplemental Figure 3B). Methods Gene expression analyses of clinical datasets and bioinformatics analyses. Overall survival (OS) and disease-free survival (DFS) data for breast cancer patients based on OSM mRNA expression in the METABRIC (19) and Wang (20) datasets were analyzed and represented using the CANCERTOOL interface (59) in combination with cBioPortal (www.cbioportal.org).

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/166463